Skip to main content

Drug Interactions between dabigatran and Olysio

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dabigatran simeprevir

Applies to: dabigatran and Olysio (simeprevir)

MONITOR: Coadministration with inhibitors of P-glycoprotein (P-gp) such as simeprevir may increase the plasma concentration of dabigatran etexilate, a substrate of the efflux transporter. When digoxin (0.25 mg once), a P-gp probe substrate, was administered with simeprevir (150 mg once a day for 7 days) in 16 healthy adults, digoxin AUC and Cmax increased by 39% and 31%, respectively.

MANAGEMENT: Product labeling advises that use of dabigatran with P-gp inhibitors in patients with severe renal impairment (CrCl less than 30 mL/min) should be avoided. In patients taking dabigatran for the treatment or prophylaxis of deep venous thrombosis (DVT) or pulmonary embolism (PE), use of dabigatran with P-gp inhibitors in moderate renal impairment (CrCl 30 to 50 mL/min) should be avoided.

References (4)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2010) "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim
  4. (2013) "Product Information. Olysio (simeprevir)." Janssen Pharmaceuticals

Drug and food interactions

Moderate

simeprevir food

Applies to: Olysio (simeprevir)

ADJUST DOSING INTERVAL: Food significantly enhances the oral bioavailability of simeprevir, although the type of food does not seem to matter. In healthy study subjects, administration of simeprevir after a high-fat, high-caloric (928 kcal) breakfast increased systemic exposure (AUC) by 61% and delayed absorption by 1 hour, while administration after a normal caloric (533 kcal) breakfast increased AUC by 69% and delayed absorption by 1.5 hours.

MANAGEMENT: To ensure maximal oral absorption, simeprevir should be administered with food.

References (1)
  1. (2013) "Product Information. Olysio (simeprevir)." Janssen Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer